HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBD Supplement Market Enforcement Based On FDA Concerns, Not Discretion

Executive Summary

Although agency is prioritizing enforcement on hemp and CBD supplement and food products marketed with violative claims and allowing sales of products compliant with its regulations, the approach is not enforcement discretion, officials say. It's aware some companies are marketing hemp and CBD products "in ways that violate the law," and its "biggest concern" is products "that put the health and safety of consumers at greatest risk."

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel